Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard ...
(RTTNews) - Actinium Pharmaceuticals, Inc. (ATNM) Tuesday has launched a clinical program evaluating Actimab-A in combination with the PD-1 inhibitors pembrolizumab - KEYTRUDA and nivolumab OPDIVO.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback